Drugs / Osteogenon
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07210281 | Nov 2024 → Feb 2027 expected | — | University of Opole | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Osteogenon | “The aim of the study was to evaluate the effect of ossein-hydroxyapatite complex (Osteogenon) as an adjunctive treatment on the outcome of conservative and surgical fractures...” NCT07210281 ↗ |
| Known as | ossein-hydroxyapatite complex | “The aim of the study was to evaluate the effect of ossein-hydroxyapatite complex (Osteogenon) as an adjunctive treatment on the outcome of conservative and surgical fractures...” NCT07210281 ↗ |
| Route | Oral | “The tablets were taken orally, one tablet twice daily.” NCT07210281 ↗ |